Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

• Sponsor: Ritter Pharmaceuticals, Inc.
• Information provided by (Responsible Party): Ritter Pharmaceuticals, Inc.

Study Description

Brief Summary:

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted in the United States (US) to assess the efficacy of RP-G28 compared to placebo on symptom reduction related to lactose intolerance.

Condition or disease	Intervention/treatment	Phase
Lactose Intolerance	Drug: RP-G28; Drug: Placebos	Phase 3

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	557 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Intervention Model Description:	This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted in the United States (US). The study is comprised of 6 study periods divided into Part A and Part B.
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
Actual Study Start Date :	June 26, 2018
Estimated Primary Completion Date :	July 2019
Estimated Study Completion Date :	July 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: RP-G28; galacto-oligosaccharide, spray-dried powder for reconstitution for oral administration, 7.5 grams 2 times per day	Drug: RP-G28; powder for reconstitution for oral administration
Placebo Comparator: Placebos; maltodextrin, powder for reconstitution for oral administration, 7.5 grams 2 times per day	Drug: Placebos; powder for reconstitution for oral administration

Outcome Measures

Primary Outcome Measures :

1. Change from baseline of the Lactose Intolerance (LI) symptom composite score compared to placebo [ Time Frame: Day 38 ]
   Change from baseline of the LI symptom composite score compared to placebo. The LI symptom composite score includes abdominal pain, abdominal bloating, abdominal cramping, and abdominal gas.

Secondary Outcome Measures :

1. Change from baseline of the LI symptom composite score compared to placebo [ Time Frame: Day 61 ]
   Change from baseline of the LI symptom composite score compared to placebo.The LI symptom composite score includes abdominal pain, abdominal bloating, abdominal cramping, and abdominal gas.

Eligibility Criteria

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Patient is 18-75 years of age, inclusive, at screening;
• Intolerance to milk and other dairy products;
• Patient agrees to refrain from all other treatments and products used for lactose intolerance, to follow diet modifications required during periods of the study that include abstinence from all dairy in some periods and consuming dairy in other periods;
• Patient meets the defined minimum lactose intolerance symptom composite score; and
• Patient has positive Hydrogen Breath Test (HBT) results for lactase deficiency.

Exclusion Criteria:

• Patient has a disorder associated with abnormal gastrointestinal motility such as gastroparesis (from any cause), amyloidosis, neuromuscular diseases (including Parkinson's disease), collagen vascular diseases, uremia, or malnutrition;
• Patient has undergone bowel preparation for endoscopic or radiologic investigation within 4 weeks of Screening (example, colonoscopy preparation);
• Patient has a history of surgery that alters the normal function of the gastrointestinal tract including, but not limited to: fundoplication, gastrointestinal bypass surgery, bariatric surgery, gastric banding, colostomy, vagotomy, pyloroplasty, colectomy or other surgery for Crohn's disease or ulcerative colitis; and
• Patient has received antibiotic treatment, or had a high colonic enema, colonic irrigation, colonic hydrotherapy, or colonic cleaning within 30 days prior to or during Screening.

Contacts and Locations

  Show 35 Study Locations

Sponsors and Collaborators

Ritter Pharmaceuticals, Inc.

Investigators

Layout table for investigator information

Study Director:	Sharron Gargosky, PhD	Ritter Pharmceuticals, Inc.

More Information

Layout table for additonal information

Responsible Party:	Ritter Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:	NCT03597516 History of Changes
Other Study ID Numbers:	G28-006
First Posted:	July 24, 2018
Last Update Posted:	March 21, 2019
Last Verified:	January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:		Yes
Studies a U.S. FDA-regulated Device Product:		No

Keywords provided by Ritter Pharmaceuticals, Inc.:

Lactose Intolerance

Additional relevant MeSH terms:

Layout table for MeSH terms

Lactose Intolerance; Malabsorption Syndromes; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases	Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Metabolic Diseases